Placebo-controlled, double-blind, exploratory study of KW-6002 (istradefylline) in the treatment of Parkinson's disease [adjunctive therapy to levodopa]

Trial Profile

Placebo-controlled, double-blind, exploratory study of KW-6002 (istradefylline) in the treatment of Parkinson's disease [adjunctive therapy to levodopa]

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top